Borosil Scientific capacity for scientific glassware is planned to rise from about 15 lakh units to 108 lakh units a year after the board approved a ₹60 crore facility at Bharuch, Gujarat. The company targets commercial production by March 2027; the real question is whether demand and product mix can absorb a more than sevenfold increase without weakening utilisation or margins.
How Borosil Scientific capacity changes
The exchange disclosure describes a new facility in Bharuch and a March 2027 production target. ALFA News independently reported the ₹60 crore approval, capacity increase and stated utilisation, while Business Standard separately reported the board’s capex decision.
The addition is 93 lakh units a year. On a simple arithmetic basis, the announced capital cost is about ₹64.5 per unit of incremental annual capacity. That is not a unit production cost: it excludes operating inputs and says nothing about product complexity, yield, depreciation or working capital.
| Metric | Disclosed figure |
|---|---|
| Approved capex | ₹60 crore |
| Existing annual capacity | About 15 lakh units |
| Planned annual capacity | About 108 lakh units |
| Increment | 93 lakh units |
| Target production date | March 2027 |
Why the utilisation signal matters
A factory operating near its practical limit can lose orders, lengthen lead times or rely on less efficient scheduling. At the stated 87% utilisation, Borosil Scientific has a plausible reason to add room before demand pushes the existing line closer to its ceiling.
In plain terms: Borosil Scientific capacity is being expanded before the current operation is completely full, giving the company room to pursue orders—but also creating a much larger sales target once the new plant starts. The expansion is substantial enough that commissioning alone will not prove success.
Manufacturing programmes frequently move through separate construction, commissioning and utilisation gates. Lapaas Voice has tracked that sequence at R R Kabel’s Silvassa unit and Transrail’s conductor expansion.
What to watch before March 2027
The next useful disclosures are land and equipment readiness, spending against the ₹60 crore budget, trial production, approvals and the product categories assigned to the new lines. Any delay would push out revenue while fixed costs and depreciation may still begin to build.
After launch, watch capacity utilisation, segment revenue, margins and inventory. Borosil Scientific describes itself as a scientific solutions provider with laboratory glassware, equipment, pharmaceutical packaging and process systems; a higher-value mix can matter as much as unit volume.
The project’s India-manufacturing angle also resembles the longer-horizon Applied Materials India investment: capital commitments are credible starting points, but repeat orders and output quality determine durable value.
Funding detail is another gap to monitor. The board disclosed the project cost, but the accessible records reviewed here do not specify the debt-equity mix, subsidy assumptions or working-capital requirement. Those choices can change the expansion cash return even if the plant reaches its stated capacity on schedule.
FAQs
How much is Borosil Scientific investing?
The board approved ₹60 crore for the additional Bharuch manufacturing facility.
How much capacity will be added?
Planned annual capacity rises by 93 lakh units, from about 15 lakh to 108 lakh units.
When is commercial production expected?
The disclosed target is March 2027, subject to project execution and required approvals.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
